Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients

Acquired resistance to BRAF/MEK-targeted therapy occurs in the majority of melanoma patients that harbor BRAF mutated tumors, leading to relapse or progression and the underlying mechanism is unclear in many cases. Using multiplex immunohistochemistry and spatial imaging analysis of paired tumor sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chi, Chen, Sheau-Chiann, Ayers, Gregory D., Nebhan, Caroline A., Roland, Joseph T., Weiss, Vivian L., Johnson, Douglas B., Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776860/
https://www.ncbi.nlm.nih.gov/pubmed/35058553
http://dx.doi.org/10.1038/s41698-021-00249-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776860/
https://www.ncbi.nlm.nih.gov/pubmed/35058553
http://dx.doi.org/10.1038/s41698-021-00249-1

Ejemplares similares